Successful Surgical Hemostasis in Patients with von Willebrand Disease following Infusion of Koate^®DVI

• References

• 1 Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
• 2 Foster PA. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. Thromb Haemost 1995; 74: 1370-8.
• 3 Cohen AJ, Kessler CM, Ewenstein BM. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America. Haemophilia 2001; 07: 235-41.
• 4 Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP).. Br J Haematol 1992; 82: 87-93.
• 5 Kasper CK, Costa e Silva M. Registry of clotting factor concentrates. In: Facts and Figures Monograph Series. World Federation of Hemophilia 2001; 1-4.
• 6 Slaby JA, Pruthi RK, Wilke JL, Fisher PK, Gilchrist GS, Nichols WL. Von Willebrand factor (vWF) concentrates: vWF multimer patterns, factor VIII and vWF content, and therapeutic efficacy. Hemophilia 2000; 06: 253.
• 7 Agrawal YP, Dzik W. The vWF content of factor VIII concentrates. Transfusion 2001; 41: 153-4.
• 8 Mathews V, Srivastava A, Nair SC, Chandy M. Haemostasis with cryoprecipitate in patients undergoing surgery for severe von Willebrand disease. Natl Med J India 2000; 13: 188-90.